Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 25036938)

1.

Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart.

Olivola E, Pierantozzi M, Imbriani P, Liguori C, Stampanoni Bassi M, Conti M, D'Angelo V, Mercuri NB, Stefani A.

PLoS One. 2014 Jul 18;9(7):e101763. doi: 10.1371/journal.pone.0101763. eCollection 2014.

2.

Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type.

Volicer L, Direnfeld LK, Freedman M, Albert ML, Langlias PJ, Bird ED.

Arch Neurol. 1985 Feb;42(2):127-9.

PMID:
2579625
3.

Depression and Parkinson's disease: possible role of serotonergic mechanisms.

Kostić VS, Djuricić BM, Covicković-Sternić N, Bumbasirević L, Nikolić M, Mrsulja BB.

J Neurol. 1987 Feb;234(2):94-6.

PMID:
2435855
5.

CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder.

Hou C, Jia F, Liu Y, Li L.

Brain Res. 2006 Jun 20;1095(1):154-8. Epub 2006 May 19.

PMID:
16713589
6.

Cerebrospinal fluid monoamine and metabolite concentrations and aggression in rats.

van der Vegt BJ, Lieuwes N, Cremers TI, de Boer SF, Koolhaas JM.

Horm Behav. 2003 Sep;44(3):199-208.

PMID:
14609542
7.

Cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in HIV-1 infection.

Kumar AM, Berger JR, Eisdorfer C, Fernandez JB, Goodkin K, Kumar M.

Neuropsychobiology. 2001;44(1):13-8.

PMID:
11408787
8.

Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations.

Loeffler DA, LeWitt PA, Juneau PL, Camp DM, DeMaggio AJ, Havaich MK, Milbury PE, Matson WR.

Neurochem Res. 1998 Dec;23(12):1521-5.

PMID:
9821156
9.
10.

Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients.

Kuhn W, Müller T, Gerlach M, Sofic E, Fuchs G, Heye N, Prautsch R, Przuntek H.

J Neural Transm. 1996;103(12):1441-5.

PMID:
9029411
11.

Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.

Kim SE, Choi JY, Choe YS, Choi Y, Lee WY.

J Nucl Med. 2003 Jun;44(6):870-6.

12.

Altered serotonin metabolism in depressed patients with parkinson's disease.

Mayeux R, Stern Y, Cote L, Williams JB.

Neurology. 1984 May;34(5):642-6.

PMID:
6200801
13.

Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms.

Tong Q, Zhang L, Yuan Y, Jiang S, Zhang R, Xu Q, Ding J, Li D, Zhou X, Zhang K.

Parkinsonism Relat Disord. 2015 May 27. pii: S1353-8020(15)00234-5. doi: 10.1016/j.parkreldis.2015.05.016. [Epub ahead of print]

PMID:
26028271
14.
15.

Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid levels in women with comorbid depression and panic disorder.

Sullivan GM, Oquendo MA, Huang YY, Mann JJ.

Int J Neuropsychopharmacol. 2006 Oct;9(5):547-56. Epub 2005 Nov 1.

PMID:
16259647
16.

5-HT and 5-HIAA in cerebrospinal fluid in depression.

Gjerris A, Sørensen AS, Rafaelsen OJ, Werdelin L, Alling C, Linnoila M.

J Affect Disord. 1987 Jan-Feb;12(1):13-22.

PMID:
2437171
17.

The effect of lumbar puncture stress on dopamine and serotonin metabolites in human cerebrospinal fluid.

Hill KK, West SA, Ekhator NN, Bruce AB, Wortman MD, Baker DG, Geracioti TD Jr.

Neurosci Lett. 1999 Nov 26;276(1):25-8.

PMID:
10586966
18.

Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.

González-Quevedo A, García JC, Fernández R, Fernández Cartaya L.

Bol Estud Med Biol. 1993 Jan-Dec;41(1-4):13-9.

PMID:
7521168
19.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
20.

CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.

Gibson CJ, Logue M, Growdon JH.

Arch Neurol. 1985 May;42(5):489-92.

PMID:
2581531
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk